Épisode 34 : Rivaroxaban et aspirine suite à une revascularisation pour maladie artérielle périphérique (étude VOYAGER PAD)

Diffusé le 15 juin 2020

Dans cette 34e baladodiffusion, les Drs Luc Lanthier et Gabriel Huard discutent de l’efficacité du rivaroxaban dans le traitement des sujets avec maladie artérielle périphérique post-revascularisation, en plus de réviser la littérature médicale de mai 2020.

Quiz clinique (1 min 03), article principal (1 min 31), critique (20 min 11), autres articles (29 min 53), réponse au quiz clinique (33 min 15)

Référence principale

Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020;382(21):1994-2004. PubMed PMID: 32222135.

Infographie

Articles associés

Creager MA. A Bon VOYAGER for Peripheral Artery Disease. N Engl J Med. 2020;382(21):2047-8. PubMed PMID: 32433842.

Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-30. PubMed PMID: 28844192.

Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219-29. PubMed PMID : 29132880.

Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 2019;157(2):403-12. PubMed PMID: 31054846.

https://www.inspq.qc.ca/sites/default/files/publications/2446_portrait_maladies_vasculaires.pdf

Autres articles d'intérêt récents

Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883-93. PubMed PMID: 32222134.

Samama CM, Laporte S, Rosencher N, Girard P, Llau J, Mouret P, et al. Rivaroxaban or or Enoxaparin in Nonmajor Orthopedic Surgery. N Engl J Med. 2020;382(20):1916‐1925. PubMed PMID: 32223113.

Thiruganasambandamoorthy V, Sivilotti MLA, Le Sage N, Yan JW, Huang P, Hegdekar M, et al. Multicenter Emergency Department Validation of the Canadian Syncope Risk Score. JAMA Intern Med. 2020;180(5):1‐8. PubMed PMID : 32202605.

Thiruganasambandamoorthy V, McRae AD, Rowe BH, Sivilotti MLA, Mukarram M, Nemnom MJ, et al. Does N-Terminal Pro-B-Type Natriuretic Peptide Improve the Risk Stratification of Emergency Department Patients With Syncope? Ann Intern Med. 2020;172(10):648-55. PubMed PMID : 32340039.

Guides de pratique récents

Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, et al. Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2020;36(5):596-624. PubMed PMID: 32389335.

Hiremath S, Sapir-Pichhadze R, Nakhla M, Gabor JY, Khan NA, Kuyper LM, et al. Hypertension Canada's 2020 Evidence Review and Guidelines for the Management of Resistant Hypertension. Can J Cardiol. 2020;36(5):625-34. PubMed PMID: 32389336.

Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, et al. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;201(9):e56-e69. PubMed PMID: 32283960.

Référence du quiz clinique

Quinn KL, Stall NM, Yao Z, Stukel TA, Cram P, Detsky AS, et al. The risk of death within 5 years of first hospital admission in older adults. CMAJ. 2019;191(50):E1369-E77. PubMed PMID: 31844021.